Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

May 31, 2025

Conditions
Gestational Diabetes
Interventions
DRUG

Metformin

"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"

DRUG

Ursodeoxycholic Acid

"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"

Trial Locations (1)

SE1 7EH

Guy's and St Thomas' NHS Foundation Trust, London

All Listed Sponsors
collaborator

Guy's and St Thomas' NHS Foundation Trust

OTHER

lead

King's College London

OTHER

NCT04407650 - Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus | Biotech Hunter | Biotech Hunter